Sector Gamma AS increased its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 2.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,386,722 shares of the biopharmaceutical company’s stock after purchasing an additional 35,000 shares during the period. Bristol-Myers Squibb accounts for 11.9% of Sector Gamma AS’s portfolio, making the stock its largest holding. Sector Gamma AS owned 0.09% of Bristol-Myers Squibb worth $70,321,000 at the end of the most recent quarter.
Several other hedge funds have also recently made changes to their positions in BMY. Garrett Wealth Advisory Group LLC bought a new stake in shares of Bristol-Myers Squibb in the 3rd quarter worth about $26,000. Lenox Wealth Advisors LLC increased its holdings in shares of Bristol-Myers Squibb by 555.7% in the 3rd quarter. Lenox Wealth Advisors LLC now owns 636 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 539 shares during the last quarter. Financial Gravity Wealth Inc. increased its holdings in shares of Bristol-Myers Squibb by 101.2% in the 3rd quarter. Financial Gravity Wealth Inc. now owns 650 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 327 shares during the last quarter. 1 North Wealth Services LLC bought a new stake in shares of Bristol-Myers Squibb in the 3rd quarter worth about $41,000. Finally, Endurance Wealth Management Inc. increased its holdings in shares of Bristol-Myers Squibb by 119.6% in the 2nd quarter. Endurance Wealth Management Inc. now owns 918 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 500 shares during the last quarter. Hedge funds and other institutional investors own 80.40% of the company’s stock.
A number of analysts have recently weighed in on BMY shares. ValuEngine downgraded shares of Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a report on Friday, October 25th. JPMorgan Chase & Co. set a $62.00 target price on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Friday, September 13th. Wolfe Research set a $66.00 target price on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Friday, November 1st. Bank of America started coverage on shares of Bristol-Myers Squibb in a report on Wednesday, October 16th. They issued a “buy” rating and a $60.00 target price on the stock. Finally, UBS Group boosted their target price on shares of Bristol-Myers Squibb from $51.00 to $53.00 and gave the stock a “neutral” rating in a report on Wednesday, October 23rd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $56.64.
Shares of BMY stock traded up $0.44 during trading hours on Friday, reaching $58.02. 11,418,626 shares of the stock were exchanged, compared to its average volume of 12,766,524. Bristol-Myers Squibb Co has a 12-month low of $42.48 and a 12-month high of $58.46. The company has a current ratio of 3.83, a quick ratio of 3.72 and a debt-to-equity ratio of 1.37. The company’s 50-day moving average price is $52.90 and its 200-day moving average price is $48.19. The firm has a market capitalization of $91.88 billion, a price-to-earnings ratio of 14.58, a price-to-earnings-growth ratio of 1.31 and a beta of 0.71.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $1.06 by $0.11. The firm had revenue of $6.01 billion during the quarter, compared to analysts’ expectations of $5.89 billion. Bristol-Myers Squibb had a net margin of 23.53% and a return on equity of 45.49%. The firm’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period in the previous year, the company earned $1.09 EPS. On average, sell-side analysts expect that Bristol-Myers Squibb Co will post 4.33 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Friday, October 4th were given a $0.41 dividend. The ex-dividend date was Thursday, October 3rd. This represents a $1.64 annualized dividend and a yield of 2.83%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 41.21%.
In other Bristol-Myers Squibb news, insider Louis S. Schmukler sold 25,000 shares of the business’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $56.56, for a total value of $1,414,000.00. Following the completion of the sale, the insider now directly owns 31,963 shares of the company’s stock, valued at approximately $1,807,827.28. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP John E. Elicker sold 15,000 shares of the business’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $56.66, for a total transaction of $849,900.00. Following the completion of the sale, the senior vice president now directly owns 74,471 shares of the company’s stock, valued at $4,219,526.86. The disclosure for this sale can be found here. 0.13% of the stock is owned by insiders.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Read More: After-Hours Trading
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.